Monica Diez-Fairen1, Gabrielle Houle2, Sara Ortega-Cubero3, Sara Bandres-Ciga4, Ignacio Alvarez1, Maria Carcel1, Laura Ibañez5, Maria Victoria Fernandez5, John P Budde5, Jean-Rémi Trotta6, Raúl Tonda6, Jessica X Chong7, Michael J Bamshad8, Deborah A Nickerson9, Miquel Aguilar1, Juan P Tartari1, Alexandre Gironell10, Elena García-Martín11, Jose Ag Agundez11, Hortensia Alonso-Navarro12, Felix Javier Jimenez-Jimenez12, Manel Fernandez13, Francesc Valldeoriola14, Maria Jose Marti14, Eduard Tolosa14, Francisco Coria15, Maria A Pastor16, Carles Vilariño-Güell17, Alex Rajput18, Patrick A Dion19, Carlos Cruchaga5, Guy A Rouleau20, Pau Pastor21. 1. Fundació Docència i Recerca MútuaTerrassa, Movement Disorders Unit, Department of Neurology, University Hospital Mútua Terrassa, Terrassa, Barcelona, Spain. 2. Department of Human Genetics, McGill University, Montréal, Quebec, Canada; Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada. 3. Department of Neurology and Neurosurgery, Hospital Universitario de Burgos, Burgos, Spain. 4. Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Instituto de Investigación Biosanitaria de Granada (ibs. GRANADA), Granada, Spain. 5. NeuroGenomics and Informatics, Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. 6. Centre Nacional d'Anàlisis Genòmic (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain & Universitat Pompeu Fabra (UPF), Barcelona, Spain. 7. Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA. 8. Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA; Seattle Children's Hospital, Seattle, WA, 98105, USA; Department of Genome Sciences, University of Washington, Seattle, WA, USA. 9. Department of Genome Sciences, University of Washington, Seattle, WA, USA. 10. Movement Disorders Unit, Neurology Department, Hospital de Sant Pau and Sant Pau Biomedical Research Institute, Barcelona, 08026, Spain. 11. University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, Cáceres, Spain. 12. Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, Spain. 13. María de Maeztu Unit of Excellence, Institute of Neurosciences, University of Barcelona, MDM-2017-0729, Ministry of Science, Innovation and Universities, Spain; Parkinson's Disease & Movement Disorders Unit, Department of Neurology, Hospital Clínic, IDIBAPS, Barcelona, Spain. 14. Parkinson's Disease & Movement Disorders Unit, Department of Neurology, Hospital Clínic, IDIBAPS, Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, Spain. 15. Clinic for Nervous Disorders, Service of Neurology, Son Espases University Hospital, Palma de Mallorca, Spain. 16. Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain. 17. Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. 18. Saskatchewan Movement Disorders Program, University of Saskatchewan/Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada. 19. Department of Human Genetics, McGill University, Montréal, Quebec, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, H3A 2B4, Quebec, Canada. 20. Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, H3A 2B4, Quebec, Canada. 21. Fundació Docència i Recerca MútuaTerrassa, Movement Disorders Unit, Department of Neurology, University Hospital Mútua Terrassa, Terrassa, Barcelona, Spain. Electronic address: pastorpau@gmail.com.
Abstract
INTRODUCTION: Essential tremor (ET) is one of the most common movement disorders. Despite its high prevalence and heritability, its genetic etiology remains elusive with only a few susceptibility genes identified and poorly replicated. Our aim was to find novel candidate genes involved in ET predisposition through whole exome sequencing. METHODS: We studied eight multigenerational families (N = 40 individuals) with an autosomal-dominant inheritance using a comprehensive strategy combining whole exome sequencing followed by case-control association testing of prioritized variants in a separate cohort comprising 521 ET cases and 596 controls. We further performed gene-based burden analyses in an additional dataset comprising 789 ET patients and 770 healthy individuals to investigate whether there was an enrichment of rare deleterious variants within our candidate genes. RESULTS: Fifteen variants co-segregated with disease status in at least one of the families, among which rs749875462 in CCDC183, rs535864157 in MMP10 and rs114285050 in GPR151 showed a nominal association with ET. However, we found no significant enrichment of rare variants within these genes in cases compared with controls. Interestingly, MMP10 protein is involved in the inflammatory response to neuronal damage and has been previously associated with other neurological disorders. CONCLUSIONS: We prioritized a set of promising genes, especially MMP10, for further genetic and functional studies in ET. Our study suggests that rare deleterious coding variants that markedly increase susceptibility to ET are likely to be found in many genes. Future studies are needed to replicate and further infer biological mechanisms and potential disease causality for our identified genes.
INTRODUCTION: Essential tremor (ET) is one of the most common movement disorders. Despite its high prevalence and heritability, its genetic etiology remains elusive with only a few susceptibility genes identified and poorly replicated. Our aim was to find novel candidate genes involved in ET predisposition through whole exome sequencing. METHODS: We studied eight multigenerational families (N = 40 individuals) with an autosomal-dominant inheritance using a comprehensive strategy combining whole exome sequencing followed by case-control association testing of prioritized variants in a separate cohort comprising 521 ET cases and 596 controls. We further performed gene-based burden analyses in an additional dataset comprising 789 ET patients and 770 healthy individuals to investigate whether there was an enrichment of rare deleterious variants within our candidate genes. RESULTS: Fifteen variants co-segregated with disease status in at least one of the families, among which rs749875462 in CCDC183, rs535864157 in MMP10 and rs114285050 in GPR151 showed a nominal association with ET. However, we found no significant enrichment of rare variants within these genes in cases compared with controls. Interestingly, MMP10 protein is involved in the inflammatory response to neuronal damage and has been previously associated with other neurological disorders. CONCLUSIONS: We prioritized a set of promising genes, especially MMP10, for further genetic and functional studies in ET. Our study suggests that rare deleterious coding variants that markedly increase susceptibility to ET are likely to be found in many genes. Future studies are needed to replicate and further infer biological mechanisms and potential disease causality for our identified genes.
Authors: Alberto Bergareche; Marcin Bednarz; Elena Sánchez; Catharine E Krebs; Javier Ruiz-Martinez; Patricia De La Riva; Vladimir Makarov; Ana Gorostidi; Karin Jurkat-Rott; Jose Felix Marti-Masso; Coro Paisán-Ruiz Journal: Hum Mol Genet Date: 2015-10-01 Impact factor: 6.150
Authors: Simon Gravel; Brenna M Henn; Ryan N Gutenkunst; Amit R Indap; Gabor T Marth; Andrew G Clark; Fuli Yu; Richard A Gibbs; Carlos D Bustamante Journal: Proc Natl Acad Sci U S A Date: 2011-07-05 Impact factor: 11.205
Authors: Hreinn Stefansson; Stacy Steinberg; Hjorvar Petursson; Omar Gustafsson; Iris H Gudjonsdottir; Gudrun A Jonsdottir; Stefan T Palsson; Thorlakur Jonsson; Jona Saemundsdottir; Gyda Bjornsdottir; Yvonne Böttcher; Theodora Thorlacius; Dietrich Haubenberger; Alexander Zimprich; Eduard Auff; Christoph Hotzy; Claudia M Testa; Lisa A Miyatake; Ami R Rosen; Kristleifur Kristleifsson; David Rye; Friedrich Asmus; Ludger Schöls; Martin Dichgans; Finnbogi Jakobsson; John Benedikz; Unnur Thorsteinsdottir; Jeffrey Gulcher; Augustine Kong; Kari Stefansson Journal: Nat Genet Date: 2009-02-01 Impact factor: 38.330
Authors: Kailash P Bhatia; Peter Bain; Nin Bajaj; Rodger J Elble; Mark Hallett; Elan D Louis; Jan Raethjen; Maria Stamelou; Claudia M Testa; Guenther Deuschl Journal: Mov Disord Date: 2017-11-30 Impact factor: 10.338
Authors: Zagaa Odgerel; Shilpa Sonti; Nora Hernandez; Jemin Park; Ruth Ottman; Elan D Louis; Lorraine N Clark Journal: PLoS One Date: 2019-08-12 Impact factor: 3.240
Authors: Regina T Martuscello; Karthigayini Sivaprakasam; Whitney Hartstone; Sheng-Han Kuo; Genevieve Konopka; Elan D Louis; Phyllis L Faust Journal: Cerebellum Date: 2022-10-15 Impact factor: 3.648
Authors: Félix Javier Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; Ignacio Álvarez; Pau Pastor; José A G Agúndez Journal: Pharmaceuticals (Basel) Date: 2021-05-27